CA-ARMIS
Armis, the asset intelligence cybersecurity company, today announced that it has been named a Top Performer in the 2024 Best in KLAS Software & Services Report for Healthcare IoT Security for the second year in a row. The Best in KLAS report recognizes software and services companies that excel in helping healthcare professionals improve patient care.
“This recognition from KLAS which is based solely on customer reviews is a true testament to our ongoing commitment to protecting the attack surfaces of healthcare organizations,” said Mohammad Waqas, CTO of Healthcare at Armis. “I want to thank every Armis customer who took the time this year to share with KLAS their experience with Armis CentrixTM for Medical Device Security. Your feedback is instrumental in helping us continuously improve our solutions and deliver the best possible value to the healthcare community.”
The 2024 Best in KLAS report, based on independent feedback from healthcare providers in North America, evaluates vendors across six key performance areas: culture, loyalty, operations, product, relationship and value. Armis achieved an outstanding overall score, demonstrating excellence in every category and solidifying the company’s position as a leader in Healthcare IoT Security.
When asked about Armis, customers shared the following anonymized comments with KLAS in review of the company’s solution:
- “Given the nature of how sensitive and aware we have all become to some of the hazards surrounding cybersecurity and cyber risks associated with penetration into personal health information through many different avenues of medical devices and applications, the Armis application is robust in being able to see all network-connected devices. It is really incredible to see the amount of horsepower that the Armis platform brings to the table for us. The product really is a great tool. Not only can the reporting piece identify connected devices but it is able to identify what type of device something is through the product's algorithms. The product is able to determine what the make, model, and serial number are, and in some cases, what operating system the device is functioning on. Recently, we had an issue with updating the security on anything that was still running on something other than Windows 10, and through the Armis system, we were able to see how many devices were reporting through the application that were not up to Windows 10. With the reporting structure, we now have a line of sight into many things we didn't know about.” - Director, April 2023
- “Armis does very well with implementations. They are very knowledgeable about their products. They have experts on their team, so if we need some help with a configuration, they have resources available that are on standby typically to help and engage in troubleshooting.” - Analyst/Coordinator, April 2023
- “In general, Armis regularly updates their platform and gives good notifications about new enhancements and new features. They back those notifications up with written material and videos, as well as live sessions if we are lucky enough to find the time to attend them. It is good that the vendor is constantly adding new features and new capabilities to the product.” - Analyst/Coordinator, September 2023
In July 2023, Armis was rated the best-performing cross-industry vendor in the KLAS Healthcare IoT Security 2023 report for its deep coverage of IoT, OT, IoMT and IT across all verticals.
In the past year, Armis has continued to deepen its commitment to securing healthcare organizations. Combining the power of Armis CentrixTM, the cyber exposure management platform, and the Armis AI-powered Asset Intelligence Engine, Armis has reinforced its healthcare-specific capabilities which help to provide complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem with zero disruptions to patient care.
Armis is a sponsor of HIMSS 2024, taking place in Orlando, FL March 11-15. Stop by Armis’ booth #1621 in the CyberSecurity Command Center or visit the team in the Main Walkway at booth #1048. At HIMSS, Armis’ CTO of Healthcare, Mohammad Waqas, will speak to “Building a Comprehensive Healthcare Security Program for Next-Gen Patient Care.” This session will be held on Tuesday, March 12th from 10:15am - 10:30am EDT in the Orange County Convention Center, Theatre A.
To read the KLAS report, please visit: 2024 Best in KLAS - Software & Services
To learn more about Armis CentrixTM for Medical Device Security, go to: https://www.armis.com/platform/armis-centrix-for-medical-device-security/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
About KLAS Research
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212843101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe6.11.2025 08:00:00 CET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
SES Delivers Solid 9 Months and Q3 2025 Results6.11.2025 07:30:00 CET | Press release
SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the nine months and three months ended 30 September 2025 with solid operational and financial performance. Solid 9 months 2025 financial performance on a reported basis (Intelsat fully consolidated from 17 July 2025) Revenue of €1,747 million (+19.8% yoy(1)) and Adjusted EBITDA(2) of €849 million (+11.0% yoy(1)) Networks (+36.3% yoy(1)) supported by growth in Aviation and Government; Media (+0.7% yoy(1)) with important new long-term renewals signed Solid progress with company integration and synergy execution since Day 1 of transaction closure €1.4 billion of new business and contract renewals signed YTD 2025 – with a total combined gross backlog of €7.1 billion O3b mPOWER satellites 9 &10 successfully launched on 22 July, expected to be in service beginning 2026 – boosting O3b mPOWER network capacity and resilience Collected c.$87 million regarding insurance claim for O3b mPOWER satellites 1-4 w
Transition Industries and Mitsubishi Gas Chemical Sign Agreement for the Purchase and Sale of Ultra-Low Carbon Methanol6.11.2025 05:00:00 CET | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, signed a long-term methanol sales and purchase agreement with Mitsubishi Gas Chemical Company, Inc. (MGC) for the offtake of ultra-low carbon methanol. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105695992/en/ Masahiko Naito, Division Director of Mitsubishi Gas Chemical and Rommel Gallo, CEO of Transition Industries sign agreement in Tokyo, November 6, 2025 Under the Agreement, which will become effective upon the Project’s Final Investment Decision (FID), Transition Industries will supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,130 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2029. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corpora
Kinaxis Announces Normal Course Issuer Bid5.11.2025 23:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 12, 2025 and ending November 11, 2026, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,403,042 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 31, 2025. As of the close of business on October 31, 2025, the Company had 28,060,844 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased p
Hyper® Wins Dual CES 2026 Innovation Awards® for its Breakthrough Tech Accessories5.11.2025 22:45:00 CET | Press release
Hyper’s HyperSpace™ Trackpad Pro and HyperDrive® Next USB4 M.2 PCIe Enclosure named as CES Innovation Awards® 2026 Honorees Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/ CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed. The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories. “For 20 years, Hyper has led the tech accessory space with industry-defin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom